NCT06584786 Therapeutic Effects of Jing Si Herbal Tea for COPD
| NCT ID | NCT06584786 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation |
| Condition | Airway Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 120 participants in total. It began in 2022-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic obstructive pulmonary disease (COPD), a leading cause of global mortality, significantly impairs health-related quality of life (HRQL). COPD is characterized by airway inflammation and lung tissue damage. Jing Si herbal tea (JSHT) is known to have anti-inflammatory effects but has not been explored for treating COPD. This study investigated the potential of JSHT as an adjuvant therapy for COPD. This randomized controlled study focused on patients with COPD in the exacerbation and stable phases. The control group received the standard treatment, and the JSHT group received the standard treatment plus JSHT. Both groups underwent HRQL assessments, blood tests, and cellular studies involving five different groups to assess the effect of JSHT on damage-associated molecular patterns (DAMPs) and inflammatory markers.
Eligibility Criteria
Inclusion Criteria: * COPD patients willing to enter this study Exclusion Criteria: * not COPD patients, no willing to enter this study
Contact & Investigator
Chou-Chin Lan, MD
PRINCIPAL INVESTIGATOR
Taichung Tzu Chi Hospital
Frequently Asked Questions
Who can join the NCT06584786 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Airway Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06584786 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06584786 currently recruiting?
Yes, NCT06584786 is actively recruiting participants. Contact the research team at bluescopy@yahoo.com.tw for enrollment information.
Where is the NCT06584786 trial being conducted?
This trial is being conducted at New Taipei City, Taiwan.
Who is sponsoring the NCT06584786 clinical trial?
NCT06584786 is sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. The principal investigator is Chou-Chin Lan, MD at Taichung Tzu Chi Hospital. The trial plans to enroll 120 participants.